Fig. 2: Tumor response and treatment exposure in 51 LA HSCC patients. | Nature Communications

Fig. 2: Tumor response and treatment exposure in 51 LA HSCC patients.

From: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial

Fig. 2

A Percentage reduction of tumor diameter of the primary lesion compared with baseline with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 measurement. B Treatment exposure and response duration of induction chemoimmunotherapy, radioimmunotherapy, and immunotherapy maintenance in 51 patients. Source data are provided as a Source Data file.

Back to article page